PDCD1 and non-small cell lung carcinoma: In one study, 54 patients with NSCLC were treated with anti-PD-1 treatment, NLR was assessed at baseline and 6 weeks, and low post-treatment NLR (>5) and immune-related adverse events were significantly associated with low RR and shorter PFS and OS.